Please login to the form below

Not currently logged in
Email:
Password:

Deltyba

This page shows the latest Deltyba news and features for those working in and with pharma, biotech and healthcare.

Study shows Otsuka's TB drug works even in worst cases

Study shows Otsuka's TB drug works even in worst cases

Otsuka's recently-approved tuberculosis therapy Deltyba is effective even in complicated infections caused by extensively drug-resistant (XDR) strains of the bacterium, says a new study. ... Deltyba was approved for marketing last year in Europe, joining

Latest news

  • R&D productivity takes off R&D productivity takes off

    Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a

  • Otsuka wins approval for TB drug Deltyba Otsuka wins approval for TB drug Deltyba

    Otsuka Pharmaceutical's Deltyba has become the second medicine approved this year in the EU to treat multidrug resistant (MDR) forms of tuberculosis (TB). ... Otsuka challenged this recommendation, and the CHMP later recommended Deltyba after a

  • J&J gets EU green light for novel TB drug J&J gets EU green light for novel TB drug

    While wholly novel drugs to treat multidrug-resistant TB have been thin on the ground, last year saw a brace of new therapies approved in the EU, namely Otsuka's Deltyba

  • EMA to expand orphan drug HTA collaboration EMA to expand orphan drug HTA collaboration

    Deltyba and Lucane Pharma's Lucane both for multi-drug resistant tuberculosis.

  • Cell wall inhibitors for bacterial infections Cell wall inhibitors for bacterial infections

    The nitro-dihydroimidazo-oxazole derivative Delamanid (Deltyba; Otsuka Pharmaceutical) inhibits mycolic acid synthesis and thus the formation of the mycobacterial cell envelope.

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics